The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy-Reference-Cited by-同舟云学术

The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy

Published:2009-03 Issue:3 Volume:20 Page:592-595
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Vazquez-Martin A.,Oliveras-Ferraros C.,del Barco S.,Martin-Castillo B.,Menendez J.A.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/20/3/592/460102/mdn758.pdf

Reference14 articles.

1. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer;Nahta;Nat Clin Pract Oncol,2006

2. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors;Chen;Clin Cancer Res,2008

3. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition;Force;Nat Rev Cancer,2007

4. Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells;Yarden;Proc Natl Acad Sci USA,2007

5. Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells;Shell;Cell Cycle,2008

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synergistic Effects of Metformin and Trastuzumab on HER2 Positive Gastroesophageal Adenocarcinoma Cells In Vitro and In Vivo;Cancers;2023-09-28

2. Metformin and HER2-positive breast cancer: Mechanisms and therapeutic implications;Biomedicine & Pharmacotherapy;2023-06

3. Promising FDA-approved drugs with efflux pump inhibitory activities against clinical isolates of Staphylococcus aureus;PLOS ONE;2022-07-29

4. Factors influencing the anticancer effects of metformin on breast cancer outcomes: a systematic review and meta-analysis;Expert Review of Anticancer Therapy;2022-03-28

5. The effect of metformin when combined with neoadjuvant chemotherapy in breast cancer patients;Medical Oncology;2021-11-05